Mann replies: I am grateful to Dr Bushara for his interest and comments. I too had considered other potential mechanisms for the salivary gland swelling but favored duct paralysis for a number of reasons.

The patient clearly still secreted saliva as she was able to empty the glands "manually" with massaging. Parotid infection was rejected on the basis of negative growth from swabs and absent response to broad spectrum antibiotics.

The concept of paraparotic hypersecretion is intriguing but it would not explain a dry mouth to result. Duct paralysis best explains the combination of symptoms and signs in this patient.

A C MANN Department of Neurology and Clinical Neurophysiology, Southern General Hospital, 1345 Govan Road, Glasgow G51 4TF, UK

Immunoglobulin treatment in human and experimental epilepsy

The paper of van Engelen et al mentions some positive effects of intravenous immunoglobulins (IVIg) in the treatment of refractory epilepsy. No reference about our experience in that field is mentioned, however, in the available literature reviewed by Van Engelen et al.

In 1983, we successfully treated with IVIg a patient with severe Lennox-Gastaut syndrome (LGS) who still remains seizure free.1 Thereafter, in a first open study, 20 patients with Lennox-Gastaut syndrome and partial epilepsy were infused with IVIg.2 This treatment gave excellent results in two patients, who were still seizure free for months but relapsed afterwards although their seizures were less severe than before the infusions. In this open study, 15 patients have partially improved including eight with a pronounced decrease of seizures. It was concluded that IVIg treatment may be very helpful not only in West and Lennox-Gastaut syndromes, but also in partial epilepsy, including Rasmussen's syndrome.3

At that time, however, all studies published about IVIg in refractory epilepsy were open designs—with the exception of that of Illium et al., which was a single blind, cross over trial—with controversial schedules and doses. Indeed the patients received from two to more than 10 infusions with doses ranging from 100 mg to 1 g/kg/perfusion and no relation was assessed between dose or schedule of IVIg and clinical responsiveness. An overview of the medical literature involving about 200 epileptic patients treated with IVIg showed a positive response to this treatment in around 30% of the patients.4 Taking that into account, in 1989 we initiated the first double blind study to establish a dose of IVIg for treatment of epilepsy.5 Sixty one patients were randomly assigned to receive either IVIg (n = 43) or a placebo (n = 18) at three different doses (100, 250, or 400 mg/kg/infusion). No dose effect was found (P = 0.31). The data for the whole study population showed an improvement rate of 52-5% of patients treated with IVIg (in accordance with previously reported open studies), compared with 27-8% in the placebo group; this positive trend was not significant (P = 0.09). When only the patients with partial epilepsy were assessed, a significant difference in favour of the IVIg treatment was found (P = 0.04) and this was confirmed in the subgroup of partial epilepsy with secondarily generalised seizures (n = 30) regardless of the dose (P = 0.04). Two patients became seizure free. One with Lennox-Gastaut syndrome needed no further anticonvulsant medication. The other, who had partial epilepsy, relapsed but is still better than before the IVIg.

The mechanisms of action are unknown. We found some relation between a lower serum IgA level and a better clinical response in the first study,6 but could not confirm this correlation in the double blind study7 although we noted a trend in favour of a lower serum IgA level. IVIg in refractory epilepsy are well tolerated but the major problems related to this treatment concern its cost and the hazards of transmission of infectious agents to blood derivatives. Immunoglobulins may be considered safe however, as their manufacturing procedures are known to inactivate human pathogenic viruses such as hepatitis A, B and C, and HIV.8 I and K VAN RICKVEORSVEL

K VAN RICKVEORSVEL, M DELIRE Centre Neurologique William Lennox, Allée de Clairende, 6 B-1340 Oignies-LEN, Belgium

References


Van Engelen et al reply: We thank van Rijckevorsel and Delire for their interest in our paper on immunoglobulins in human and experimental epilepsy.1 Their point was that we did not mention their experience in that field. Our paper was an overview of some aspects of immunoglobulin effects in human and experimental epilepsies; it was not a review of the medical literature on immunoglobulin treatment in human epilepsies. We wrote a 1993 review on current immunoglobulin treatment in human epilepsies,2 and there we recognised their contribution in the field by citing three papers published by van Rijckevorsel and colleagues.

B G M VAN ENGELEN W O RENIER

Instituut Neuroradiologie C R M WEEMAES

Department of Neuroradiology, University Hospital, Nijmegen, The Netherlands

Immunoglobulin treatment in human and experimental epilepsy.

K Van Rijckevorsel and M Delire

J Neurol Neurosurg Psychiatry 1995 59: 105
doi: 10.1136/jnnp.59.1.105-b

Updated information and services can be found at:
http://jnnp.bmj.com/content/59/1/105.3.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/